Evolution of the Average Target: Lexeo Therapeutics, Inc.

Evolution of the Target Price: Lexeo Therapeutics, Inc.

Changes in Analyst Recommendations: Lexeo Therapeutics, Inc.

2.YLdE_rDTqQuYYWNQK0LikPbhmwfUFJ2-58iAdwCLriA.JN8Iutq04G7IPiY9bxSM9NvSrj7mcvDOt5vSBTXH1BYSxjWH55eaUskRVw~8fa324d887e846696afea640fbde2a56
12-18 Raymond James Initiates Coverage on Lexeo Therapeutics With Strong Buy Rating, $25 Price Target MT
11-20 Cantor Fitzgerald Initiates Coverage on Lexeo Therapeutics With Overweight Rating, $19 Price Target MT
15/10/25 Guggenheim Initiates Coverage on Lexeo Therapeutics With Buy Rating, $30 Price Target MT
08/10/25 Chardan Raises Price Target on Lexeo Therapeutics to $17 From $15, Keeps Buy Rating MT
07/10/25 Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy CI
07/10/25 Lexeo Says FDA Open to Application Submission for Accelerated Approval of Friedreich Ataxia Cardiomyopathy Treatment MT
07/10/25 Lexeo Shares Rise On Progress for Heart Disease Treatment DJ
18/08/25 Chardan Cuts Price Target on Lexeo Therapeutics to $15 From $20, Keeps Buy Rating MT
31/07/25 Oppenheimer Initiates Lexeo Therapeutics at Outperform With $20 Price Target MT
13/05/25 Chardan Adjusts Price Target on Lexeo Therapeutics to $20 From $22, Maintains Buy Rating MT
08/04/25 Chardan Research Adjusts Lexeo Therapeutics Price Target to $22 From $25, Maintains Buy Rating MT
25/03/25 RBC Cuts Price Target on Lexeo Therapeutics to $20 From $24, Keeps Outperform, Speculative Risk MT
13/06/24 Baird Initiates Lexeo Therapeutics With Outperform Rating, $28 Price Target MT
06/06/24 HC Wainwright Initiates Lexeo Therapeutics at Buy With $22 Price Target MT
12/03/24 RBC Raises Price Target on Lexeo Therapeutics to $24 From $22, Cites 'Solid' Friedreich's Ataxia Data; Outperform, Speculative Risk Kept MT
28/11/23 Chardan Initiates Lexeo Therapeutics With Buy Rating, $23 Price Target MT
28/11/23 Stifel Starts Lexeo Therapeutics With Buy Rating, $20 Price Target MT
28/11/23 RBC Initiates Lexeo Therapeutics at Outperform, Speculative Risk With $22 Price Target Amid 'Undemanding' Valuation, Upcoming Catalysts MT
28/11/23 JPMorgan Starts Lexeo Therapeutics With Overweight Rating, $20 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+500.59%
+11.79%
+21.92%
+19.64%
+7.4%
+25.43%
+18.27%
+50.7%
+3.91%
+73.24%
Average +73.29%
Weighted average by Cap. +22.53%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.380USD
Average target price
20.30USD
Spread / Average Target
+500.59%
High Price Target
30.00USD
Spread / Highest target
+787.57%
Low Price Target
9.000USD
Spread / Lowest Target
+166.27%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
  1. Stock Market
  2. Stocks
  3. LXEO Stock
  4. Consensus Lexeo Therapeutics, Inc.